STOCK TITAN

Vanguard disaggregates holdings; GILD reporting shows 0 shares (Vanguard)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Gilead Sciences Inc filing shows an amended Schedule 13G/A from The Vanguard Group reporting that, after an internal realignment, Vanguard and certain subsidiaries will report holdings separately and that The Vanguard Group beneficially owns 0 shares of Common Stock (0%).

The amendment explains the disaggregation is made in accordance with SEC Release No. 34-39538 and states related subsidiaries pursue the same investment strategies previously used; signature dated 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports zero beneficial ownership following internal realignment.

The filing states The Vanguard Group will report certain subsidiaries separately and that the Group itself holds 0 shares, representing 0% of the class. This is a structural reporting change rather than a market transaction.

Impact depends on the separate reports from the disaggregated entities; subsequent filings may show where holdings reside.

Amendment cites SEC Release No. 34-39538 to disaggregate beneficial ownership.

The filing explicitly ties the reporting change to SEC Release No. 34-39538 (January 12, 1998) and states subsidiaries will report separately. The statement clarifies The Vanguard Group, Inc. no longer is deemed to beneficially own those subsidiary-held securities.

Stakeholders should refer to the separate schedules filed by Vanguard subsidiaries for the actual holdings.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report in the GILD Schedule 13G/A amendment?

The filing states The Vanguard Group reports 0 shares beneficially owned, representing 0%. It explains an internal realignment caused subsidiaries to report holdings separately under SEC Release No. 34-39538.

Does the Schedule 13G/A show Vanguard sold GILD shares?

No—this amendment explains a reporting disaggregation, not a sale. It attributes the change to an internal realignment and separate reporting by subsidiaries per the cited SEC release.

Which SEC release does Vanguard cite for the disaggregation?

The amendment cites SEC Release No. 34-39538 (January 12, 1998). It uses that release to justify separate reporting by subsidiaries following Vanguard's internal realignment.

When was the Vanguard Schedule 13G/A signed for GILD?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026. The amendment header references 03/13/2026 as the amendment date.

Will Vanguard still manage GILD positions after this amendment?

The amendment states subsidiaries pursue the same investment strategies as before and that The Vanguard Group no longer is deemed to beneficially own those subsidiary-held securities. Separate schedules will show actual positions.
Gilead Sciences Inc

NASDAQ:GILD

View GILD Stock Overview

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

171.45B
1.24B
Drug Manufacturers - General
Biological Products, (no Diagnostic Substances)
Link
United States
FOSTER CITY